Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Postcolonoscopy colorectal cancer (PCCRC) represents an important real-world colonoscopy quality indicator. Using a national database, we evaluated predictors of PCCRC in fecal immunochemical test (FIT)-positive individuals, determined the PCCRC 3-year (PCCRC-3y) rate, and performed a root cause analysis (RCA).
Methods: This retrospective cohort study evaluated FIT-positive patients who underwent colonoscopy from January 2015 to July 2022. Data were collected from the Veterans Affairs national database. PCCRC was defined as CRC detected ≥6 months after colonoscopy. CRC was identified using Systematized Nomenclature of Medicine codes and the Veterans Affairs Cancer Registry. The World Endoscopy Organization methodology was used to perform the RCA and calculate the PCCRC-3y rate.
Results: We identified 132 PCCRCs among 52,167 FIT-positive individuals. The PCCRC-3y rate was 6.4% (95% confidence interval [CI] 5.0%-7.7%). PCCRC locations were proximal colon (43.2%), distal colon (34.8%), and rectum (22%). Root causes were likely new CRC (17.4%), missed lesions with adequate (31.2%) or inadequate (9.8%) examination, incomplete polyp resection (22%), and detected but unresected lesions (19.7%). 16.7% of patients with PCCRC had poor bowel preparation on index colonoscopy. The cecal intubation rate was 88.6%, and rectal retroflexion rate was 84.5%. In 14.4% of cases, recommended surveillance intervals did not adhere to established guidelines. Independent predictors of PCCRC were ages 70-79 years (hazard ratio [HR] 7.86; 95% CI 1.08-57.39), age ≥80 years (HR 10.18; 95% CI 1.06-97.98), tubulovillous adenoma (HR 3.98; 95% CI 2.52-6.29), and adenoma with high-grade dysplasia (HR 10.15; 95% CI 5.91-17.42).
Discussion: Among FIT-positive individuals, the PCCRC-3y rate was 6.4%, with missed lesions and incomplete resection as key contributors. These findings provide useful information on quality metrics in FIT-based CRC-screening programs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14309/ajg.0000000000003635 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic Accuracy of the Faecal Immunochemical Test in Triage of Symptomatic Patients Referred for Colonoscopy: A Prospective Single-Centre Study.
Can J Gastroenterol Hepatol
September 2025
Department of Gastroenterology, St Luke's General Hospital, Kilkenny, Ireland.
The faecal immunochemical test (FIT) is endorsed by NICE for triaging symptomatic patients referred from primary care. This prospective diagnostic accuracy study assessed the performance of FIT in detecting significant colorectal pathology among symptomatic patients referred for colonoscopy in secondary care. Between May 2023 and May 2024, FIT kits were distributed to 1296 adult patients referred for lower gastrointestinal (GI) endoscopy.
View Article and Find Full Text PDFAdded value of a balloon-based mucosal exposure device in computer-aided detection-assisted colonoscopy: a randomized controlled trial (COMBAT study).
Endoscopy
August 2025
Gastroenterology Unit, Valduce Hospital, Como, Italy.
Both computer-aided detection (CADe) systems and mucosal exposure devices can enhance adenoma detection during colonoscopy. This research investigates whether combining a CADe system with a balloon-based mucosal exposure device increases the identification of individuals with high risk colonoscopy findings within a fecal immunochemical test (FIT)-based organized screening program.We conducted a multicenter, open-label, parallel-arm randomized controlled trial.
View Article and Find Full Text PDFTriaging colorectal urgent referrals in the COVID-19 era using faecal immunochemical testing: a prospective UK real-world multicentre cohort study.
BMJ Open Gastroenterol
July 2025
Colorectal Surgery, North Devon District Hospital, Barnstaple, UK.
Objective: During the early COVID-19 pandemic, UK guidelines advocated faecal immunochemical tests (FIT) with a threshold of 10 µg/g to help secondary care clinicians triage urgent suspected colorectal cancer (CRC) referrals. We aimed to evaluate the real-world performance and impact of FIT in a high-risk cohort referred against National Institute for Health and Clinical Excellence NG12 (2015) criteria.
Methods: Multicentre prospective observational cohort study of FIT at all four secondary care hospitals in Devon (UK) between 1 April 2020 and 31 December 2020.
Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test-Positive Individuals: Prevalence, Predictors, and Root Cause Analysis in a Nationwide Cohort.
Am J Gastroenterol
July 2025
Division of Gastroenterology, New York University Grossman School of Medicine, New York, New York, USA.
Introduction: Postcolonoscopy colorectal cancer (PCCRC) represents an important real-world colonoscopy quality indicator. Using a national database, we evaluated predictors of PCCRC in fecal immunochemical test (FIT)-positive individuals, determined the PCCRC 3-year (PCCRC-3y) rate, and performed a root cause analysis (RCA).
Methods: This retrospective cohort study evaluated FIT-positive patients who underwent colonoscopy from January 2015 to July 2022.
A Cohort Study Analysing the Impact of the COVID-19 Pandemic on Colorectal Cancer Presentations in a Medium-Large Canadian Community Hospital.
Cancer Control
July 2025
Schulich School of Medicine, University of Windsor, Windsor, ON, Canada.
IntroductionColorectal Cancer (CrC) is a common cause of cancer-related death worldwide, but screening programs are highly effective at diagnosing early-stage disease, allowing effective treatment. During COVID-19, a decrease in screening participation was hypothesized due to limited access, leading to an increase in symptomatic presentations and stage at diagnosis.MethodsAll patients who met inclusion criteria were divided into two cohorts based on time of diagnosis ( = 373).
View Article and Find Full Text PDF